Myfortic

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
49Systemic lupus erythematosus4
66IgA nephropathy2
222Primary nephrotic syndrome3
IDDisease name (Link within this page)Number of trials
223Primary membranoproliferative glomerulonephritis1
228Bronchiolitis obliterans2

49. Systemic lupus erythematosus


Clinical trials : 1,414 / Drugs : 1,077 - (DrugBank : 181) / Drug target genes : 130 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 407 / Drugs : 342 - (DrugBank : 73) / Drug target genes : 40 - Drug target pathways : 146 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 576 / Drugs : 519 - (DrugBank : 130) / Drug target genes : 108 - Drug target pathways : 219 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

223. Primary membranoproliferative glomerulonephritis


Clinical trials : 243 / Drugs : 296 - (DrugBank : 84) / Drug target genes : 46 - Drug target pathways : 169 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

228. Bronchiolitis obliterans


Clinical trials : 112 / Drugs : 139 - (DrugBank : 31) / Drug target genes : 33 - Drug target pathways : 161 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries